SGK-1 inhibitor relieves atopic dermatitis symptoms in vivo and exerts synergistic effects with JAK inhibitor. (IMAGE)
Caption
(A) Effect of delgocitinib and/or GSK 650394 on DNCB/OVA-induced atopic dermatitis in dorsal skin (B) Hematoxylin-eosin staining of dorsal skin tissue sections (C) Effects of delgocitinib and/or GSK 650394 on dermatitis scores in DNCB-induced atopic dermatitis (D) Effects of delgocitinib and/or GSK 650394 on trans-epidermal water loss (TEWL) in DNCB/OVA-induced atopic dermatitis (E) Representative immunohistochemistry images of skin lesions for LOR and FLG in delgocitinib and/or GSK 650394-treated mice. Scale bar: 50 μm (F) Western blotting analysis of FLG and LOR in dorsal skin tissue of DNCB/OVA-induced atopic dermatitis mice treated with delgocitinib and/or GSK 650394 (G) Quantitative reverse transcription PCR assay of the related target mRNA levels in skin lesions from mice receiving different treatments. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 (H) Related target molecules secretion (ELISA) of mouse model blood from different groups (n = 5) (I) Proposed working model of how NaCl modulates keratinocytes' function in atopic dermatitis. Data are shown as the mean ± standard deviation from at least three independent experiments. Statistical analysis was performed using Student's t-test. Data are expressed as mean ± standard deviation. ∗∗p < 0.01 and ∗∗∗p < 0.001.
Credit
Yingqiang Luo, Zhiqiang Song, Pengju Jiang, Lan Ge, Min Zhang, Zihao Zhou, Yaguang Wu, Jun Hu
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND